Table 2.
Comparisons of PET indices in whole body tumors according to clinicopathologic parameters (n=109)
| Variable | SUVmax | p-value | MTV (mL) | p-value | TLG | p-value |
|---|---|---|---|---|---|---|
| Age (yr) | ||||||
| < 45 | 3.99±2.44 | 0.099 | 5.15±3.81 | 0.042 | 13.84±13.92 | 0.038 |
| ≥ 45 | 5.09±3.24 | 7.77±6.46 | 22.54±28.90 | |||
| Histology | ||||||
| IDC | 5.04±3.07 | < 0.001 | 7.22±5.75 | 0.409 | 21.19±26.52 | 0.196 |
| Non-IDC | 2.01±1.08 | 5.49±8.32 | 9.47±16.79 | |||
| T stage | ||||||
| T1 | 4.12±2.29 | 0.014 | 5.40±5.14 | 0.001 | 12.17±13.29 | < 0.001 |
| T2 | 5.65±3.70 | 9.19±6.33 | 30.46±33.71 | |||
| LVI | ||||||
| Negative | 4.75±3.10 | 0.570 | 7.01±6.00 | 0.671 | 19.90±26.39 | 0.551 |
| Positive | 5.42±2.84 | 8.04±5.92 | 24.97±20.37 | |||
| No. of positive LNs | ||||||
| 1 | 4.43±2.59 | 0.101 | 6.22±5.23 | 0.051 | 15.84±17.40 | 0.020 |
| 2, 3 | 5.43±3.71 | 8.54±6.90 | 27.79±35.37 | |||
| Positive LNs (%) | ||||||
| < 25 | 4.82±3.10 | 0.695 | 7.17±5.98 | 0.507 | 20.34±26.25 | 0.852 |
| ≥ 25 | 4.31±2.89 | 5.49±6.10 | 18.28±23.14 | |||
| ECE | ||||||
| Negative | 4.81±3.08 | 0.869 | 6.97±5.61 | 0.546 | 19.20±21.59 | 0.532 |
| Positive | 4.63±3.25 | 8.23±9.52 | 31.57±56.55 | |||
| Histological grade | ||||||
| 1, 2 | 3.97±2.59 | < 0.001 | 6.04±5.02 | 0.004 | 14.05±16.20 | 0.002 |
| 3 | 7.73±2.85 | 10.93±7.40 | 42.04±38.88 | |||
| Estrogen receptor status | ||||||
| Negative | 6.66±4.03 | 0.008 | 9.50±6.19 | 0.020 | 33.72±31.19 | 0.014 |
| Positive | 4.24±2.50 | 6.35±5.75 | 16.21±22.96 | |||
| Progesterone receptor status | ||||||
| Negative | 5.52±3.53 | 0.028 | 9.22±7.00 | 0.001 | 29.37±32.93 | 0.002 |
| Positive | 4.22±2.55 | 5.39±4.38 | 13.03±15.74 | |||
| HER2 overexpression | ||||||
| Negative | 4.73±2.64 | 0.818 | 6.77±5.38 | 0.538 | 17.44±18.66 | 0.237 |
| Positive | 4.90±3.98 | 7.63±7.10 | 25.64±37.16 |
PET, positron emission tomography; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; IDC, invasive ductal carcinoma; LVI, lymphovascular invasion; LN, lymph node; ECE, extracapsular extension.